Chung, Seung Yeun
Chang, Jee Suk
Choi, Min Seo
Chang, Yongjin
Choi, Byong Su
Chun, Jaehee
Keum, Ki Chang
Kim, Jin Sung
Kim, Yong Bae
Funding for this research was provided by:
National Research Foundation of Korea (2019R1C1C1009359)
Article History
Received: 23 December 2020
Accepted: 11 February 2021
First Online: 25 February 2021
Ethics approval and consent to participate
: This study was approved by the institutional review board of Severance Hospital of the Yonsei University Health System (IRB: 4–2019-0339). Consent was waived due to the retrospective nature of the study.
: Not applicable.
: Dr. Chang reports grants from National Research Foundation of Korea (NRF) while the study was being conducted. In addition, Dr. Chang has a patented prediction method for normal tissue region prediction, with royalties paid from OncoSoft, Coreline Soft Co., Ltd., and reports being an OncoSoft Company Shareholder. Dr. Chang YJ reports being an Employee of Coreline Soft Co., Ltd. Dr. Kim JS reports a patented prediction method for normal tissue region prediction, with royalties paid from OncoSoft, Coreline Soft Co., Ltd., and being the OncoSoft Company CEO. Dr. Kim YB reports a patented prediction method for normal tissue region prediction, with royalties paid from OncoSoft, Coreline Soft Co., Ltd., and being an OncoSoft Company Shareholder.